AACR 2021 | IMbrave150: updated data on atezo plus bev versus sorafenib in HCC

Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III IMbrave150 trial (NCT03434379) investigating atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). At a median of 15.6 months atezo plus bev reported a greater median overall survival and median progression-free survival versus sor, regardless of risk categorization. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.